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Abstract: The Staphylococcus aureus toxin, α-hemolysin, is an important and well-studied virulence
factor in staphylococcal infection. It is a soluble monomeric protein that, once secreted by the
bacterium, forms a heptameric pore in the membrane of a broad range of host cell types. Hemolysin
was recently discovered to bind and activate a disintegrin and metalloprotease 10 (ADAM10).
In epithelial and endothelial cells, ADAM10 activation is required for the toxin’s activity against
these cells. In host monocytic cells, α-hemolysin activates the nucleotide-binding domain and
leucine-rich repeat containing gene family, pyrin domain containing 3 (NLRP3) inflammasome
leading to production of pro-inflammatory cytokines and cell death. We now show that ADAM10 is
critical for α-hemolysin-mediated activation of the NLRP3 inflammasome in human monocytes as
siRNA knockdown or chemical blockade of ADAM10-α-hemolysin interaction leads to diminished
inflammasome activation and cell death by reducing the available ADAM10 on the cell surface.
Unlike epithelial cell and endothelial cell damage, which requires α-hemolysin induced ADAM10
activation, ADAM10 protease activity was not required for NLRP3 inflammasome activation.
This work confirms the importance of ADAM10 in immune activation by α-hemolysin, but indicates
that host cell signal induction by the toxin is different between host cell types.
Keywords: NLRP3; ADAM10; α-hemolysin
1. Introduction
Staphylococcus aureus is a gram-positive bacterium that is responsible for causing infections that
lead to severe morbidity and mortality. S. aureus causes infections in a broad range of host tissues
including the skin, vascular, and respiratory systems [1]. It is also a growing public health concern
because of the emergence of antibiotic resistance including methicillin resistant strains that cause both
hospital and community acquired infections [2–4].
Staphylococcus aureus produces an array of virulence factors that are important for the pathogenesis
of infections caused by these bacteria. Among these virulence factors are several pore-forming toxins
that attack host cells by permeabilizing their cell membranes. The pore-forming toxin, α-hemolysin
(Hla) is one of the best studied of these factors and is critical for virulence in mouse models of infections
caused by S. aureus [5–8]. Hla is active against cells from a variety of tissues including respiratory
epithelium, endothelium, immune cells, and keratinocytes [8]. This broad range of cellular targets
stems from the nearly universal expression of the host cellular receptor for Hla, A Disintegrin and
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Metalloproteinase-10 or ADAM10 [9]. Additionally, the level of ADAM10 expression on a given cell
type dictates sensitivity to the toxin [9]. Genetic loss or chemical inhibition of ADAM10 protects
cellular targets from Hla in tissue culture and mitigates Hla-induced pathology in mice [9–14]. Further,
mice treated with ADAM10 inhibitors or with tissue specific knock out of ADAM10 exhibit resistance
to S. aureus infection. In epithelial and endothelial cells, Hla’s interaction with ADAM10 leads to
the activation of ADAM10’s metalloproteinase activity. This enhanced protease activity leads to
the cleavage of cell surface adhesins, like E-cadherin, and disruption of cell-to-cell contacts [9,12].
Consequently, it is believed that activation of ADAM10 by Hla is important for S. aureus ability to
penetrate epithelial and endothelial barriers and thus cause invasive infection.
Hla is also a potent activator of the innate immune signaling protein, Nucleotide-binding domain
and Leucine-Rich repeat containing family Pyrin domain containing 3 (NLRP3) inflammasome [15,16].
The active NLRP3 inflammasome is a protein complex containing NLRP3 and the apoptosis-associated
speck-like protein containing a caspase recruitment domain (ASC) which is responsible for activation
of the cysteine proteinase caspase-1. Active caspase-1 then goes on to proteolytically process the
cytosolic, pro-inflammatory cytokines pro-IL-1β and pro-IL-18 into their active, secreted forms [17,18].
In addition, NLRP3 activation leads to a program of necrotic cell death termed pyroptosis [18–20].
Mice with genetic deletion of Nlrp3 have diminished inflammation in Hla-induced pneumonitis
models and decreased severity of infection in a mouse model of Staphylococcal pneumonia [21].
Conversely, in murine models of S. aureus skin infection IL-1β production is important for proper
bacterial clearance [13,22]. In this study, we sought to determine the role of Hla induced ADAM10
activation in the NLRP3 inflammasome signaling pathway. We show that in human monocytes
ADAM10 mediates NLRP3 activation and that the level of ADAM10 cell surface expression and not its
protease activity, is important for NLRP3 activation.
2. Results and Discussion
2.1. ADAM10 Expression Is Required for α-Hemolysin Induced Cell Death in Human Monocyte-Derived Cells
Previous work has shown ADAM10 to be important for the activity of α-hemolysin (Hla) towards
a variety of host cell types [9,11,12]. Loss of expression of ADAM10 using either siRNA in immortalized
human epithelial cells or tissue specific genetic knock-out in mouse epithelial cells blocks Hla induced
cell death [9]. Lung epithelium specific knock out of the ADAM10 gene protects mice from pulmonary
injury induced by Hla inhalation or live S. aureus instillation [10]. Targeted deletion of ADAM10 in
mouse myeloid cells also protects them from Hla induced death in a murine pneumonia model [13].
We sought to confirm that ADAM10 expression is required for human monocytic cell responsiveness
to Hla. Monocytic THP1 cells were transfected with siRNA directed against ADAM10 (both individual
siRNAs and pooled siRNA) and after three days cell surface expression was characterized by flow
cytometry. We were able to achieve significant reductions in detectable cell surface expression of
ADAM10 as compared to our non-targeting siRNA controls (Figure 1B–D). Immunoblot analysis
also showed reductions of total ADAM10 (Figure 1E). Because it has previously been shown that
NLRP3 expression is required for Hla-induced cell death in monocytes, siRNA directed to NLRP3
were used as a positive control. While siRNA directed to NLRP3 reduced NLRP3 expression levels,
it had no effect on ADAM10 levels measured by flow cytometry or immunoblot (Figure 1C–E).
siRNA transfected THP1 cells were then treated with Hla and cytolysis was subsequently assessed by
measuring release of cytosolic LDH into the culture supernatant. Depletion of NLRP3 or ADAM10
by siRNA significantly reduced Hla-induced LDH release as compared with controls (Figure 1F).
To demonstrate the effect of ADAM10 depletion was specific to Hla-induced cell death and not
generally suppressive of NLRP3 activation, siRNA transfected cells were also treated with nigericin,
a pore forming toxin known to activate NLRP3, and assessed for cell death [23]. As expected, NLRP3
depletion blocked nigericin-induced death while ADAM10 depletion had no effect (Figure 1G).
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Figure 1.  (A) Histogram  showing  staining with ADAM10‐directed antibody  compared  to  isotype 
control measured by flow cytometry. (B–D) THP1 cells were transfected with the indicated siRNA 
three days prior to assessing ADAM10 cell surface expression via flow cytometry, as detailed in the 
experimental methods section and demonstrated in (A). (B) The relative surface expressed ADAM10 
mean fluorescence intensity of THP1 cells transfected with 4 different siRNA targeting ADAM10 as 
compared to the non‐targeting control siRNA transfected cells; (C) Histogram showing fluorescence 
intensity of ADAM10 staining between cells transfected with non‐targeting siRNA and siRNA pools 
targeting  Lamin,  NLRP3,  and  ADAM10;  (D)  The  relative  surface  expressed  ADAM10  mean 
fluorescence intensity of siRNA pool transfected THP1 cells as compared to the non‐targeting control. 
For both (B,D), n = 3; (E) Whole cell  lysates from cells transfected with the  indicated siRNA pools 
were analyzed by immunoblot analysis with antibodies for ADAM10, NLRP3, and Actin as a loading 
control; (F,G) siRNA‐transfected THP1 cells were treated with α‐hemolysin (Hla) or Nigericin (Nig) 
for 1 h. Culture supernatants from untreated and toxin‐treated cells were assayed for LDH production 
as  compared  to  a  detergent‐lysis  control  (n  =  3);  For  (B,D),  ****  indicates  statistically  significant 
difference from Non‐Tg transfected cells (p ≤ 0.0001) determined by one‐way ANOVA with Dunnett’s 
multiple comparisons testing; For (F,G), ** and *** indicates statistically significant difference from 
Non‐Tg transfected cells (p ≤ 0.01 and p ≤ 0.001 respectively) determined by two‐way ANOVA testing 
with Dunnett’s multiple comparison testing. 
i r 1. ( ) ist r s i st i i it - ir ct ti c r t is t
tr l r fl c t tr . ( ) ll r tr f t it t i i t i
t i t s i ll i i fl t t , t il i t
i t l t ti i ). ( l ti f
fl i ll tr i iff r t si t r ti
t t -t ti tr l si tr sf t ll ; ( ) ist r s i fl r sc
i t it f t i i t ll t f t it - ti i i l
t r eting Lamin, NLRP3, and ADAM10; (D) The relative surface expressed ADAM10 mean fluorescence
intensity of s RNA po l transfected THP1 cells as compared to the non-targ ting control. For both
(B,D), n = 3; (E) Whole cell lysat s from cells transfected with the indicated siRNA pools were
analyzed by immunoblot analysis w th antibodies for ADAM10, NLRP3, and Actin as a l i
trol; (F,G) siRNA-transfected THP1 cells were treated with α-hemolysin (Hla) or Nigericin (Nig) for
1 h. Culture supernatan s from untreated and toxin-treat d cells were ass yed for LDH production as
compared to a deterg nt-lysis control ( = 3); For (B,D), **** indicates statistically significant difference
from Non-Tg transfected cell (p ď 0.0001) determined by one-wa ANOVA with Dunnett’s multiple
comparisons testing; For (F,G), ** and *** indicates statistically significant differe ce from Non-Tg
transfected cells (p ď 0.01 and p ď 0.001 respectively) determined by two-way ANOVA testing with
Dunnett’s multiple comparison testing.
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2.2. ADAM10 Expression Is Required for Hla-Mediated NLRP3 Inflammasome Activation in Monocytes
Hla-induces inflammatory cell death by activating the NLRP3 inflammasome in monocytes [15].
Activation of the NLRP3 inflammasome leads to activation of the cysteine proteinase caspase-1 and
subsequent processing and secretion of the cytokines IL-1β and IL-18 [17]. To determine whether
ADAM10 is required for Hla-mediated NLRP3 activation, THP1 cells transfected with individual
siRNA directed against ADAM10 as well as pooled siRNA targeting ADAM10 and NLRP3 were
challenged with α-hemolysin and IL-1β secretion by the cells as well as activation of caspase-1 were
assessed. Cells depleted of ADAM10 expression using four different siRNA against ADAM10 all
demonstrated a marked reduction in IL-1β secretion when compared to non-targeting control siRNA
(Figure 2A). Caspase-1 activation was assessed by accumulation of a fluorescent inhibitor of caspase-1
(caspase-1 FLICA) after toxin administration. Knockdown of ADAM10 or NLRP3 by pooled siRNA
transfection of THP1 cells significantly decreased caspase-1 activation in response to Hla (Figure 2B,C).
Cells depleted of ADAM10 or NLRP3 expression by transfection of pooled siRNA exhibited markedly
reduced release of IL-1β in response to Hla exposure (Figure 2D). To test whether ADAM10 depletion
effected NLRP3 activation in general or only in response to Hla, siRNA-transfected cells were treated
with nigericin or ATP, which activates NLRP3 through activation of the purogenic P2X7 receptor [24].
ADAM10 knockdown did not affect secretion of IL-1β after treatment with either ATP or nigericin
(Figure 2D). In contrast to the reductions in Hla-induced IL-1β secretion observed after transfection
with NLRP3 or ADAM10 directed siRNA, secretion of MIP-1α, a cytokine that is not dependent on
caspase-1 proteolysis for secretion, was not reduced at all in these cells relative to the control siRNA
transfected cells (Figure 2E). Thus, ADAM10 expression is critical for NLRP3 activation by Hla but not
by other NLRP3 activating stimuli.
2.3. The Protease Activity of ADAM10 Is Not Required for Hla-Mediated Activation of NLRP3-Induced
Cell Death
Chemical inhibition of ADAM10 using GI254023X, a specific inhibitor of ADAM10 reduces
Hla-mediated cytotoxicity and cleavage of extracellular E-cadherin in epithelial and endothelial
cells [10,12,25]. To determine whether the protease activity of ADAM10 was required for Hla-induced
NLRP3 activation, we treated cells with TAPI2, a non-specific metalloprotease inhibitor or GI254023X.
THP1 cells were treated with inhibitor for 15–30 min prior to challenge with Hla. Short-term
treatment of THP1 cells (15–30 min) with these inhibitors did not reduce Hla-induced cytotoxicity
(Figure 3A,B). Inoshima et al. demonstrated that treatment of epithelial cells with GI254023X led to
diminished ADAM10-mediated E-cadherin cleavage within minutes of addition of the inhibitor [10].
To ensure short-term treatment with ADAM10 inhibitors could suppress protease activity in the 30 min
time-frame of our experiments, we tested the effect of the inhibitors on measurable protease activity.
We found that TAPI2 and GI254023X were able to immediately impact the rate of peptide substrate
cleavage by purified ADAM10 (Figure 3C). Further, total metalloproteinase activity in intact THP1
cells was immediately diminished by the addition of TAPI2 (Figure 3D). Combined these results
demonstrate that the proteinase activity of ADAM10 is not required α-hemolysin-induced cell death.
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Figure 2. THP1 cells were  treated with  the  indicated siRNA  three days prior  to assessment, as  in 
Figure 1. siRNA‐transfected THP1 cells were treated with LPS (100 ng/mL) for 3 h before the addition 
of  an NLRP3  simulating  agent  for  1 h. Cell  culture  supernatants were  then  assayed  for  cytokine 
production. For some analysis the relative secretion of cytokine as compared with toxin‐treated, non‐
targeting siRNA‐transfected control cells  is plotted.  (A) absolute  (top) and relative  (bottom)  IL‐1β 
secretion in hemolysin treated THP1 cells transfected with individual ADAM10 siRNAs (n = 3). (B) 
THP1 cells transfected with the  indicated siRNA pool were treated with Caspase‐1 FLICA reagent 
prior to the addition of α‐hemolysin for 30 min. Cells are then washed, fixed and assayed by flow 
cytometry.  Representative  histograms  showing  caspase‐1  FLICA  reagent  based  fluorescence  in 
resting (left) and α‐hemolysin‐treated (right) cells previously transfected with the indicated siRNA; 
(C) Caspase‐1 FLICA activation mean fluorescence intensity in cells treated with hemolysin (n = 3); 
(D) Relative IL‐1β secretion as compared with non‐targeting control in cells treated with α‐hemolysin 
(n = 7),  top, ATP  (n = 4), middle, and nigericin  (n = 3), bottom;  (E) Relative MIP1‐α  secretion as 
compared with non‐targeting control in cells treated with hemolysin (n = 3) or nigericin (n = 3); For 
(A,D)  ** and  ****  indicate statistically significant difference  from Non‐Tg  (p  ≤ 0.01 and p  ≤ 0.0001, 
respectively) determined by one‐way ANOVA with Dunnett’s multiple comparisons testing; For (C) 
**  Indicates  statistically  significant difference  between no  treatment  and Hla  treatment  (p  ≤  0.01) 
determined by one‐way ANOVA with Sidak’s multiple comparision testing. 
i r . T P1 cells ere treated it t e i ic te si t ree s ri r t ss ss t, s i
i r . i -tr f t 1 cells were treated with LPS (100 ng/mL) for 3 h before the addition of
an NLRP3 simulating agent for 1 h. Cell culture s pe natants were then assayed for cytokine production.
For some analy is the relative s cr tion of cytoki e as c mpared with toxin-treated, non- argeti g
siRNA-transfected control cells is p otted. (A) absolute (top) and relative (bottom) IL-1β secretion in
hemolysin treated THP1 cells transfe ted with individual ADAM10 siRN s (n = 3). (B) THP1 cells
transfected with the indicated siRNA pool were treated with C spase-1 FLICA r agent prior to the
additi n of α-hemolysin for 30 mi . Cells are then w shed, fixed an assayed by flow cytometry.
Representative hi tograms s owing caspase-1 FLICA reagent based fluor scence in resting (l ft) and
α-hemo ysin-treated (right) cells previously transfected with the indicated siRNA; (C) Ca pase-1
FLI A activation me n fluorescence intensity in cells treated with hemolysin (n = 3); (D) Relative
IL-1β secretion as compared with non-targeting cont ol i cells t eated with α-h molysin (n = 7), top,
ATP (n = 4) middle, and nigericin ( = 3), bottom; (E) Relative MIP1-α secretion as compared with
non-t geting control in cells treated with hemolysin (n = 3) r nigericin (n = 3); For (A,D) ** and
**** indic te statistically significant difference from Non-Tg (p ď 0.01 and ď . 001, respectively)
determined by one-way ANOVA with Dunnett’s multipl comparisons testing; For (C) ** Indicates
statistic lly significant difference between o treatme t and Hla treatment (p ď 0.01) determined by
one-way ANOVA with Sidak’s multiple comparision testing.
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Figure 3.  (A,B) THP1 cells were  incubated with either GI254023X or TAPI2  inhibitors or  inhibitor 
vehicle (DMSO for GI254023X or H2O for TAPI2) for 30 min, propidium iodide (PI) was then added 
to the cells followed by treatment with either nothing (untreated, n = 3), α‐hemolysin (Hla, n = 3), or 
nigericin (Nig, n = 3) for 1 h. Cell death was assessed by measuring cells that stained positive for PI 
using flow cytometry. (C) Purified recombinant ADAM10 protein was mixed with vehicle (square), 
20 μM GI254023X (upward triangle) or 100 μM TAPI2 (downward triangle) and immediately assayed 
for  ADAM10  protease  activity  as  described  in  the  Materials  and  Methods  for  60  min  with 
measurements taken every five minutes; (D) Metalloprotease activity was measured in THP1 cells by 
incubating intact cells with a fluorogenic peptide substrate and measuring fluorescent intensity every 
2 min. After 10 min,  the metalloproteinase  inhibitor TAPI2  (100 μM) or vehicle was added  to  the 
reaction and fluorescence intensity was measured an additional 30 min. 
2.4. Inhibitors of ADAM10 Protease Activity Reduce Hla‐Mediated Activation of the NLRP3 Inflammasome 
through down Regulation of Surface ADAM10 Levels 
In contrast  to  the  findings with  short‐term  inhibition of ADAM10, overnight  treatment with 
GI254023X diminished Hla‐mediated but not nigericin‐induced cytotoxicity  in THP1 cells  (Figure 
4A). Overnight treatment with TAPI2, also caused a downward trend in Hla‐induced death, though 
this did not meet statistical significance (Figure 4B). Overnight treatment with TAPI2 or GI254023X 
inhibited Hla‐induced IL‐1β secretion but not nigericin‐induced IL‐1β secretion in THP1 cells while 
30 min  inhibitor  treatment  had  no  effect  on  IL‐1β  secretion  (Figure  4C–F)  Because  inhibition  of 
ADAM10  protease  activity  did  not  immediately  diminish  Hla‐induced  NLRP3  inflammasome 
activation, we tested whether prolonged inhibitor treatment altered NLRP3 expression levels using 
immunoblot analysis. Levels of NLRP3 were not altered by treatment of THP1 cells with GI254023X 
for 20 h (Figure 5A), consistent with the continued response of these cells to nigericin (Figure 4D,F). 
We then sought to determine whether chemical inhibition altered the quantity of surface expressed 
ADAM10. Treatment of THP1 cells with either inhibitor for 30 min had no significant effect on cell 
surface expression of ADAM10 detectable by  flow cytometry. After 20 h,  treated THP1 exhibited 
diminished detectable surface ADAM10  (Figure 5A–C). To better understand  the  time dependent 
difference in the response of THP1 cells treated with these inhibitors, we assessed the ADAM10 cell 
surface expression over time during treatment with GI254023X using flow cytometry. Cell surface 
Fig re 3. ( , ) 1 cells ere inc bate ith either I254023 or I2 inhibitors or inhibitor
e icle ( f r I254023 r 2 f r I2) f r 30 i , r i i i i e ( I) as t e a e
t t c lls f llo ed by treatment with either nothing (untreated, n = 3), α-hemolysin (Hla, n = 3),
or nigericin (Nig, n = 3) for 1 h. C ll death was assessed by measuring cells that stained positive
for PI using fl w cytometry. (C) Purified recombinant ADAM10 protein was mixed with vehicle
(square), 0 µM GI254023X (upward triangle) or 100 µM TAPI2 (downward triangle) and immedi tely
assayed for ADAM10 protease activity as d scr bed in the Materi ls and Methods for 60 in
ta en every five minutes; (D) Metalloprotease act vity was measured in THP1 cells
by incubati g intact cells with a fluorogenic peptide substrate and measuring fluoresce t ntensit
every 2 min. After 10 min, the metalloproteinase inhibitor TAPI2 (100 µM) or vehicle was added t
fl iti l i .
2.4. Inhibitors of 10 rotease ctivity educe la- ediated ctivation of the L 3 Infla aso e
fi -
i inished Hla-mediated but not nigericin-induced cytotoxicity in THP1 cells (Figure 4A).
Overnight trea m n with TAPI2, also cau ed downward trend in Hla-i duced death, though is did
not meet statistical significance (F gure 4B). Ov rnight treatmen wi h TAPI2 or GI254023X inhibited
Hla-induced IL-1β secretion but n t nigericin-indu ed IL-1β secretion in THP1 cells while 30 min
inhib tor treatment had no effect on IL-1β secretion (Figure 4C–F) B cause inhibition of ADAM10
protease activity did not mme iately di inish Hla-induced NLRP3 inflammasome activation, w
tested wheth r prolonged inhibitor tr atment altered NLRP3 expression levels u ing immunoblot
analysis. Levels of N RP3 were not altered by treatment of THP1 cells with GI254023X for 20 h
(Figure 5A), consistent with the continued response of the cells to nigericin (Figure 4D,F). We then
soug t to determine whether chemical inhibition altered the quantity of surface expressed ADAM10.
Treatment of THP1 cells with either nhibitor for 30 min had no significant effe t on cell surface
expression of ADAM10 detectable by flow cytometry. After 20 h, treated THP1 exhibited diminish
etectabl surfa e ADAM10 (Figure 5A–C). To better unders and the time ep ndent difference
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in the response of THP1 cells treated with these inhibitors, we assessed the ADAM10 cell surface
expression over time during treatment with GI254023X using flow cytometry. Cell surface expression
of ADAM10 decreased over time when compared to vehicle treated cells. As expected, the loss of
ADAM10 expression was accompanied by similar reductions in Hla-induced IL-1β secretion at the
corresponding timepoints in THP1 cells (Figure 5D,E). To ensure the effects of ADAM10 inhibition
on ADAM10 cell surface expression and Hla-induced IL-1β was not limited to THP1 cells, we tested
whether prolonged GI254023X exposure in U937 cells had an effect on ADAM10 levels and IL-1β
secretion. U937 cells treated with GI254023X phenocopied effects observed with THP1 cells (Figure 6).
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Figure 4.  (A,B) THP1 cells were  incubated with either GI254023X or TAPI2  inhibitors or  inhibitor 
vehicle (DMSO for GI254023X or H2O for TAPI2) for 20 h, propidium iodide (PI) was then added to 
the cells followed by treatment with either nothing (untreated, n = 3), α‐hemolysin (Hla, n = 3), or 
nigericin (Nig, n = 3) for 1 h. (C–F) THP1 cells were  incubated with the  indicated  inhibitors either 
overnight (20 h) or for 30 min. Cells were subsequently incubated with LPS for 3 h followed by no 
addition (untreated, n = 3), α‐hemolysin (Hla, n = 3), or nigericin (Nig, n = 3) for one hour. Cell‐culture 
supernatants were  then  collected  and  assayed  for  IL‐1β.  Results  are  reported  as  either  relative 
secretion to secretion from vehicle exposed cells subsequently treated with the indicated toxin (Hla 
or Nig). * and ***  indicates statistically significant difference  from vehicle  treated cells  intoxicated 
with Hla (p ≤ 0.05 or p ≤ 0.001, respectively) determined by one‐way ANOVA with Dunnett’s multiple 
comparisons testing. 
( , ) ll t it
for GI254023X or H2O for TAPI2) for 20 h, propid um iodide (PI) was then added to the
cells fo lowed by treatm n with either nothing (untreated, n = 3), α-hemolysin (H a, n = 3), or nigericin
(Nig, n = 3) for 1 h. (C–F) THP1 cells were incubated with the indicated in ibitors either overnight (20 h)
r for 30 min. Cells were subsequ ntly incubated with LPS for 3 h followed by no addition (untreated,
n = 3), α-hemolysin (Hla, n = 3), or nigericin (Nig, n = 3) for one hour. Cell-culture supernatants we
then collected and assayed for IL-1β. Results are reported as either rel tive sec etion to secretion from
vehicle exposed cells subsequently treated with the indicated toxin (Hla or Nig). * and *** indicates
statistically significant difference from vehicle treate cells intoxicated with Hla (p ď 0.05 or p ď 0.001,
respectively) determined by one-way ANOVA with Dunnett’s multiple comparisons testing.
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Figure 5. (A) Cells were treated with either vehicle (DMSO) or GI254023X for 20 h and cell lysates 
were analyzed by immunoblot for NLRP3 and Actin (loading control) as indicated. Lysates from three 
separate vehicle treated cell populations and three separate GI254023X‐treated cell populations were 
tested.  (B)  Representative  histograms  showing  the  cell  surface  staining  in  vehicle‐  or ADAM10 
inhibitor‐treated THP1 cells at either 0 or 20 h of inhibitor treatment; (C) THP1 cells were treated with 
GI254023X, TAPI2, or vehicle overnight or 15–30 min before flow cytometric analysis of ADAM10 cell 
surface expression. Each bar represents  the mean of  the mean  fluorescent  intensity of cell surface 
staining from multiple experiments (n = 3) (D–F) THP1 cells were treated with GI254023X or DMSO 
for  0,  3,  6 h, or overnight before  flow  cytometric  analysis of ADAM10  cell  surface  expression or 
treatment with α‐hemolysin was carried out as above. (n = 3) For (C), *** and **** Indicates statistically 
significant reduction when compared to vehicle‐treated controls (p ≤ 0.001 and p ≤ 0.0001, respectively) 
determined  by  one‐way  ANOVA  with  Dunnett’s  multiple  comparisons  testing;  for  (D,E),  **** 
Indicates statistically significant reduction when compared to vehicle treated control at the same time 
point (p ≤ 0.0001) determined by two‐way ANOVA with Sadik’s multiple comparisons testing. 
Figure 5. (A) Cells were treated with either vehicle (DMSO) or GI254023X for 20 h and cell lysates
were analyzed by immunoblot for NLRP3 and Actin (loading control) as indicated. Lysates from
three separate vehicle treated cell populations and three separate GI254023X-treated cell populations
were tested. (B) Representative histograms showing the cell surface staining in vehicle- or ADAM10
inhibitor-treated THP1 cells at either 0 or 20 h of inhibitor treatment; (C) THP1 cells were treated with
GI254023X, TAPI2, or vehicle overnight or 15–30 min before flow cytometric analysis of ADAM10
cell surface expression. Each bar represents the mean of the mean fluorescent intensity of cell surface
staining from multiple experiments (n = 3) (D–F) THP1 cells were treated with GI254023X or DMSO
for 0, 3, 6 h, or overnight before flow cytometric analysis of ADAM10 cell surface expression or
treatment with α-hemolysin was carried out as above. (n = 3) For (C), *** and **** Indicates statistically
significant reduction when compared to vehicle-treated controls (pď 0.001 and pď 0.0001, respectively)
determined by one-way ANOVA with Dunnett’s multiple comparisons testing; for (D,E), **** Indicates
statistically significant reduction when compared to vehicle treated control at the same time point
(p ď 0.0001) determined by two-way ANOVA with Sadik’s multiple comparisons testing.
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Figure 6. (A) U937 cells were treated with GI254023X or vehicle for 20 h and ADAM10 cell surface 
expression measured. (B) PMA‐differentiated U937 cells were treated with GI254023X or vehicle for 
20 h prior to treatment with α‐hemolysin. For (A) *** Indicates statistically significant reduction when 
compared  to  vehicle  treatment  (p  ≤  0.0001)  determined  by  paired  t‐test;  for  (B)  ****  Indicates 
statistically significant when compared to vehicle treated control cells (p ≤ 0.0001) determined by one‐
way ANOVA with Sadik’s multiple comparisons testing. 
3. Experimental Section 
3.1. siRNA Transfection of THP1 Cells 
THP1 cells were purchased from ATCC (Manassas, VA, USA). THP‐1 cells were maintained in 
RPMI 1640 media  (Gibco. Thermo Fisher Scientific, Waltham, MA. USA) supplemented with 10% 
Fetal calf serum and Penicillin and Streptomycin as described  in prior studies  [15,26]. Cells were 
transfected with  the TransIT‐TKO®  transfection  reagent  from Mirus  (Madison, WI, USA) per  the 
manufacturers protocol (product #: MIR 2150). Cells were transfected with 50 nM of pooled siRNA 
constructs  in 6 well plates. siRNAs were obtained  from  the GE/Dharmacon  (Lafayette, CO, USA) 
siGENOME library. A set of 4 siRNA was ordered for both ADAM10 (product #: D‐004503‐01‐0002, 
D‐004503‐03‐0002, D‐004503‐04‐0002, D‐004503‐05‐0002) and NLRP3  (product #: D‐017367‐01‐0002, 
D‐017367‐02‐0002, D‐017367‐03‐0002, D‐017367‐04‐0002)  and pooled prior  to  transfection. Control 
siRNA used,  include LaminA/C  (product  #: D‐001050‐01‐05),  and  a pool of non‐targeting  siRNA 
(Non‐targeting siRNA 2, 4, and 5) (#: D‐001210‐02, D‐001210‐04, D‐001210‐05), were ordered  from 
GE/Dharmacon (Lafayette, CO, USA) as well. Cells were incubated for 3 days after transfection prior 
to use in subsequent experiments. 
Immunotblot Analysis 
Western blots were performed  as done by Craven  et  al.  [15]. Primary  antibodies used were 
Adipogen Life Sciences (San Diego, CA, USA)    anti NLRP3 monoclonal antibody (#: AG‐20B‐0014‐
C100) and ABCAM (Cambridge, MA, USA) anti‐ADAM10 rabbit polyclonal (#: ab1997). Blots were 
imaged using a FluorChem E system from ProteinSimple (San Jose, CA, USA) 
3.2. Treatment of Cells with Inhibitors 
GI254023X was purchased from TOCRIS Bioscience (Bristol, UK) (product #: 3995) or Sigma (St. 
Louis, MO, USA, product #: SML0789) and resuspended in DMSO to either 10 mM or 20 mM stocks. 
TAPI2 was purchased from Enzo Life sciences (Farmingdale, NY, USA, product #: BML‐PI135‐0001) 
or Sigma (product #: SML04020, St. Louis, MO, USA) and resuspended in pyrogene free water to 10 
mM.  Cells  were  then  treated  with  vehicle  or  inhibitor  as  indicated  before  to  challenge  with 
inflammasome activating stimuli. 
3.3. Treatment of Cultured Cells with Inflammasome Activators for Cytokine Studies 
THP‐1 and U937 cells were suspended  in RPMI 1640 media (Gibco, Thermo Fisher Scientific, 
Waltham, MA. USA) supplemented with 10% Fetal calf serum and Penicillin and Streptomycin at 1 
×  106  cells/mL  and  plated  in  tissue  culture  treated  24  or  48 well  plates. U937  cells were  treated 
-
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to vehicle treatment (pď 0.0001) determined by paired t-test; for (B) **** Indicates statistic lly
ignificant whe compared to vehicle treated control cells (pď 0.0001) determined by one-way ANOVA
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1640 media (Gibco. Thermo Fisher Scientific, Waltham, MA. USA) supplemented with 10% Fetal
calf serum and Penicillin and Streptomycin as described in prior studies [15,26]. Cells were tran fected
with the TransIT-TKO® transfection re gent fr m Mirus (Madison, WI, USA) per the manufacturers
protocol (product #: MIR 2150). Cells were transfected wi h 50 nM of pooled siRNA c nstructs in
6 well plates. siRNAs were obtained from the GE/Dhar acon (Lafayette, CO, USA) siGenome library.
A set of 4 siRNA was ordered for both ADAM10 (product #: D-004503-01-0002, - - 3- ,
- - 4- , - - 5- ) and NLRP3 (product #: D-017367-01-0002, - - 2- ,
- - 3- - - 4- ) and pooled prior to transfection. Contr l siRNA used, include
LaminA/C (product #: D-001050-01-05), and a pool of non-targeting siRNA (Non-targeting siRNA 2, 4,
and 5) (#: D-001210-02, D-001210-04, D-001210-05), were ordered from GE/Dharmacon (Lafay tte, CO,
USA) as well. Cells were incubated for 3 days aft r transfection prior t use in ubseque t experiments.
Immunotblot Analysis
Western blots were performed as done by Craven et al. [15]. Primary antibodies used were
Adipogen Life Sciences (San Diego, CA, USA) anti NLRP3 monoclonal antibody (#: AG-20B-0014-C100)
and ABCAM (Cambridge, MA, USA) anti-ADAM10 rabbit polyclonal (#: ab1997). Blots were imaged
using a FluorChem E system from ProteinSimple (San Jose, CA, USA).
3.2. Treatment of Cells with Inhibitors
GI254023X was purchased f om TOCRIS Bioscience (Bristol, UK) (product #: 3995) or Sigma
(St. Louis, MO, USA, product #: SML0789) and resuspended in DMSO to either 10 mM or 20 mM stocks.
TAPI2 was purchased from Enzo Life sciences (Farmingdale, NY, USA, product #: BML-PI135-0001) or
Sigma (product #: SML04020, St. Louis, MO, USA) and resuspended in pyrogene free water to 10 mM.
Cells were then treated with vehicle or inhibitor as indicated before to challenge with inflammasome
activating stimuli.
3.3. Treatment of Cultured Cells with Inflammasome Activators for Cytokine Studies
THP-1 and U937 cells were suspended in RPMI 1640 media (Gibco, Thermo Fisher Scientific,
Waltham, MA. USA) supplemented with 10% Fetal calf serum and Penicillin and Streptomycin at
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1 ˆ 106 cells/mL and plated in tissue culture treated 24 or 48 well plates. U937 cells were treated
overnight with phorbol 12-myristate 13-acetate (PMA) (Sigma, St. Louis, MO, USA product #:
P1585). When indicated, the NLRP3 inflammasome was primed in the cells by treatment with E. coli
lipopolysaccharide (Invivogen, San Diego, CA, USA, product #: tltl-3pelps) at a concentration of
100 ng/mL for 3 h. Recombinant α-hemolysin prepared as described by Craven et al. [15], α-hemolysin
(30 µg/mL), Nigericin (50 µM) (Sigma, St. Louis, MO, USA product #: N7143) or ATP (100 mM) was
added at the indicated concentrations to induce NLRP3 inflamamsome activation. After 1 h, cells
and supernatants were collected by centrifugation at 17,000 ˆg for 3 min. Cell culture supernatants
were stored frozen at ´80 ˝C until assayed for cytokine content. LDH activity was measured in
supernatants using the Cyto-tox ONE kit (Promega, Madision, WI, USA, product #: G7891) read on
a Perkin Elmer inspire plate reader. IL-1β was measured in cell culture supernatants using either
Perkin Elmer Alphalisa (Product #: AL220C, Waltham, MA, USA) or BD bioscience (product #: 557953,
San Jose, CA, USA) ELISA kits as per manufacturer protocols.
3.4. Treatment of Cultured Cells with Inflammasome Activator for Cell Death Studies
Cells were suspended in fresh media at 1 ˆ 106 cells/mL and plated in tissue culture treated 24 or
48 well plates. Recombinant α-hemolysin was prepared as described by Craven et al. [15]. Cells were
treated with α-hemolysin (30 µg/mL) or Nigericin (50 µM) at the indicated concentrations to induce
NLRP3 inflamamsome activation. After 1 h, Cells and supernatants were collected by centrifugation at
17,000ˆ g for 3 min. Prior to the end of the experiment a control group of cells were lysed using 1%
Triton X-100 as a lysis control. Cell culture supernatants were stored frozen at ´80 ˝C until assayed for
LDH production.
3.5. Propidium Iodide Studies
Cells were suspended in fresh media at 1 ˆ 106 cells/mL and plated in tissue culture treated
48 well plates at 300 µL per well. Propidium Iodide was added to cells 5 min prior NLRP3 activating
stimuli. Cells were incubated for 1 h prior to cells being washed once with PBS and fixed using BD
stabilizing fixative (product #: 338036, San Jose, CA, USA). Cells were then assayed by flow cytometry
for Propidium iodide staining on a BD Accuri C6 flow cytometer (San Jose, CA, USA).
3.6. Measurement of Caspase-1 Activity in Treated Cells
Caspase-1 activity was measured using the FLICA® 660 caspase-1 assay far-red fluorescence kit,
(Product #: 9122) from ImmunoChemistry Technologies LLC (Bloomington, MN, USA). Cells were
plated in a 48 well at 300 uL per well at 1ˆ 106 cells/mL. The FLICA reagent was added and incubated
with cells for 15 min prior to the addition of the indicated inflammasome activator. Cells were then
incubated for an additional 30 min, transferred to 1.5 mL tubes, and washed twice with PBS. Cells were
resuspended in 300 uL of PBS and 50 uL of supplied fixative. Accumulation of fluorescent caspase-1
inhibitor was assayed by flow cytometry on a BD Accuri C6 flow cytometer (San Jose, CA, USA).
3.7. Measurement of ADAM10 Cell Surface Immunofluorescence Staining Protocol
siRNA transfected cells were resuspended in 2% BSA in 1 ˆ PBS with 0.1% sodium azide at a
concentration of 1 ˆ 107 cells/mL. One-hundred microliters of cells were added into sterile tubes with
5 uL of either PE mouse IgG1, κ Isotype control Ab from Biolegend (San Diego, CA, USA) (product
#: 400113) or PE anti-human CD156c (ADAM10) from Biolegend (product #: 352703). Cells were
incubated with antibodies for 15–20 min in the dark at 4 ˝C. Cells were then twice washed with 2 mL
of buffer and spun down at 350G for 5 min. Cells were resuspended in 500 uL of buffer prior to being
analyzed by flow cytometry on a BD Accuri C6 flow cytometer (San Diego, CA, USA).
In the inhibitor time course, assays cells were resuspended in fresh RPMI media at a concentration
of 1 ˆ 106 cells/mL. Cells were plated at 300 uL per well in a 48 well sterile tissue culture treated
plate. Inhibitors and vehicle controls were added at the indicated times after which cells were washed
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with 500 uL of cell staining buffer from Biolegend® (San Diego, CA, USA) (product #: 420201) and
spun down at 2500 RPM for 3 min. Cells were resuspended in 100 uL of cell staining buffer prior
to the addition of 5 uL of either PE mouse IgG1, κ Isotype control Ab from Biolegend (product #:
400113, San Diego, CA, USA) or PE anti-human CD156c (ADAM10) from Biolegend (product #: 352703,
San Diego, CA, USA). The plate was incubated at 4 ˝C for 15–20 min in the dark; after which the
cells were washed twice with 500 uL of cell staining buffer, spun down at 2500 RPM for 3 min and
resuspended in a final volume of 300 uL prior to being analyzed by flow cytometry on a BD accuri C6
flow cytometer.
3.8. Measurement of Metalloprotease Activity in Cells Treated with TAPI2
Metalloprotease activity was measured using the Mca-P-L-A-Q-A-V-Dpa-R-S-S-S-R-NH2
Fluorogenic Peptide Substrate III from R & D systems (catalog #: ES003, Minneapolis, MN, USA).
THP1 cells were resuspended at a concentration of 1 ˆ 106 cells/ml in 25 mM Tris buffer at a pH 8.0
as per manufacturers protocol. The assay was run in a 96 well plate in a 100-µL reaction with a final
concentration of 10 µM of substrate per well. Reads were done every 2 min and TAPI2 100 µM or
vehicle were added after 12 min and reads continued for 30 min.
3.9. Purified ADAM10 Activity Assay
This assay was conducted using the SensoLyte® 520 ADAM10 Activity Assay from ANASPEC
(Fremont, CA, USA) as per manufacturers protocol (Catalog #: 72226). GI254023X was used a final
concentration of 20 µM and TAPI2 100 µM.
4. Conclusions
ADAM10 is important for α-hemolysin binding to target cells [9]. In addition, Hla binding leads
to increased ADAM10 proteolytic activity in keratinocytes, endothelial cells, and epithelial cells [9–12].
This increased activity leads to disruption in cell-to-cell contacts through cleavage of E-cadherin and
plays a key role in S. aureus pathogenesis. In addition to causing disruption of cell-to-cell contacts,
Hla is known to induce potent pro-inflammatory signals in myeloid cells, including the production
of IL-1β and induction of programmed necrotic cell death [15]. These pro-inflammatory actions of
Hla require host cell NLRP3 inflammasome activity [15]. Targeted deletion of ADAM10 in myeloid
cells results in diminished lung levels of IL-1β in a mouse model of S. aureus pneumonia [13]. In a
S. aureus sepsis model, elimination of ADAM10 from platelets and myeloid lineages resulted in
diminished IL-1β observed in liver homogenates, decreased lung and liver pathology, and decreased
mortality in mice [14]. We have now shown that ADAM10 is required for Hla to activate the NLRP3
inflammasome in human monocytes (Figure 2). Our data suggest that the diminished tissue levels
of IL-1β observed in these mouse models lacking ADAM10 are the direct result of diminished
inflammasome activation in myeloid cells from the infected animals. Interestingly, loss of ADAM10
has also been implicated in lung epithelial injury from other bacterial pore-forming toxins, like
pneumolysin from Streptococcus pneumonia [10]. We have demonstrated that myeloid cell ADAM10
is not required for NLRP3 activation by nigericin, a second pore-forming toxin. The difference in
ADAM10 requirement for cellular injury between epithelial cells and monocytic cells in response to
pore-forming toxins other than Hla may have to do with role of ADAM10 proteolytic activation in
those cell types.
In mice, ADAM10 inhibitors prevent the loss epithelial integrity that is typically induced by
S. aureus Hla during infections of the skin and lung [10,11]. The enhancement of ADAM10 proteolytic
activity by Hla is clearly tied to that aspect of infection pathogenesis, which is likely important for
the bacteria to establish invasive infection of the tissues the toxin is acting on. However, in published
studies of S. aureus infection in mice lacking ADAM10 in myeloid lineage cells, the role of ADAM10
proteolytic activity, as opposed to high-affinity Hla binding, remains unknown. Our data now
demonstrate that ADAM10 proteolytic activity is not required for host inflammasome activation
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in isolated immune cells. Because inhibitors of ADAM10 proteolytic activity ultimately result in
reduced levels of myeloid cell surface expression of ADAM10, these inhibitors can still reduce
Hla-induced inflammasome activation. These data suggest that in myeloid cells ADAM10-facilitated
targeting of Hla to the cell is sufficient for NLRP3 inflammasome activation, which leads to both IL-1β
secretion and cell death. The exact mechanism by which these inhibitors lower ADAM10 cell surface
expression remains to be explored. ADAM10 is known to undergo autoproteolysis, it is possible
that processing is important for maturation and/or proper trafficking of ADAM10 [27]. Although
we have not demonstrated that pharmacologic ADAM10 inhibition reduces cell surface ADAM10
expression on other cell types, our findings open the possibility that ADAM10 inhibitors may improve
outcomes in murine S. aureus infection models through multiple mechanisms including both reduction
in ADAM10-mediated adherence factor cleavage and reduction of Hla-receptor on multiple cell
types. Further, the mechanisms by which Hla activates NLRP3 remain to be elucidated but are also
still potentially attractive therapeutic targets for adjunctive therapy to antibiotic therapy in severe
S. aureus infections.
In mouse models, the consequences of the loss of Hla activity towards myeloid cells differs based
on the location of infection. The loss of ADAM10 in the immune cell compartment or global loss
of NLRP3 was beneficial to the host in a mouse pneumonia model of S. aureus infection, reducing
mortality compared to mice with intact ADAM10 or NLRP3 [13]. Loss of ADAM10 from the myeloid
lineage is deleterious to the host in the skin infection model of mouse staphylococcal disease by
leading to increased lesion size and bacterial burden [13]. Prior studies by our group and others have
tied Hla-induced inflammasome activation to worsened host outcomes in S. aureus infections [21].
Genetic deletion of NLRP3 improved clinical parameters in mouse pneumonia without effecting
pathogen burden, suggesting that blunting the inflammasome mediated inflammatory response to
S. aureus could be beneficial even after infection is established [21]. This combination of findings
suggested that inhibition of ADAM10 could be an attractive mechanism to reduce deleterious effects
of robust inflammatory response during severe S. aureus infection. Because the effects of Hla on
myeloid derived human cells is likely redundant to several other pore-forming, immune cell-restricted
toxins, known as leukotoxins, made by S. aureus, the role of Hla activity on immune cells in human
infection is unknown. Like Hla, these leukotoxins also activate the NLRP3 inflammasome [26,28].
Thus, during S. aureus infection, the host inflammasome will be activated in immune cells regardless
of the interaction between ADAM10 and Hla. The role of the NLRP3 inflammasome in mediating
Hla effects on non-immune cells remains another open question in the field. Several studies have
shown Hla antibody titers are important predictors of disease outcome in patients with S. aureus
infections [29,30]. Gaining a better understanding of how Hla specifically contributes to human disease
by targeting leukocytes and other cell types will be an important step in the development of novel,
specific therapies for Staphylococcal disease.
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